Janux Therapeutics (JANX) Competitors $24.28 +1.01 (+4.34%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$24.40 +0.13 (+0.51%) As of 05/16/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. BPMC, TLX, SRPT, LEGN, TGTX, VRNA, AXSM, ADMA, NUVL, and GRFSShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), TG Therapeutics (TGTX), Verona Pharma (VRNA), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Nuvalent (NUVL), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Sarepta Therapeutics Legend Biotech TG Therapeutics Verona Pharma Axsome Therapeutics ADMA Biologics Nuvalent Grifols Janux Therapeutics (NASDAQ:JANX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation. Does the MarketBeat Community believe in JANX or BPMC? Blueprint Medicines received 510 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 68.23% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4470.97% Underperform Votes1829.03% Blueprint MedicinesOutperform Votes55468.23% Underperform Votes25831.77% Is JANX or BPMC more profitable? Blueprint Medicines has a net margin of -13.19% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Blueprint Medicines -13.19%-77.49%-20.84% Which has more risk and volatility, JANX or BPMC? Janux Therapeutics has a beta of 3.24, suggesting that its share price is 224% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Which has stronger earnings & valuation, JANX or BPMC? Janux Therapeutics has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$9.34M153.90-$58.29M-$1.36-17.85Blueprint Medicines$562.12M11.68-$67.09M-$2.47-41.17 Do institutionals & insiders have more ownership in JANX or BPMC? 75.4% of Janux Therapeutics shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend JANX or BPMC? Janux Therapeutics currently has a consensus price target of $95.25, suggesting a potential upside of 292.30%. Blueprint Medicines has a consensus price target of $126.56, suggesting a potential upside of 24.46%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Blueprint Medicines 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media favor JANX or BPMC? In the previous week, Janux Therapeutics had 7 more articles in the media than Blueprint Medicines. MarketBeat recorded 24 mentions for Janux Therapeutics and 17 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.54 beat Janux Therapeutics' score of 1.44 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 16 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 16 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryJanux Therapeutics beats Blueprint Medicines on 14 of the 19 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$6.44B$5.36B$8.52BDividend YieldN/A2.65%4.94%4.11%P/E Ratio-20.759.1627.0220.03Price / Sales153.90248.22390.46119.71Price / CashN/A65.8538.2534.62Price / Book3.256.456.764.60Net Income-$58.29M$143.73M$3.23B$248.70M7 Day Performance-5.01%4.48%4.83%5.15%1 Month Performance-18.22%7.84%9.88%14.04%1 Year Performance-48.45%-4.99%15.35%6.76% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.3422 of 5 stars$24.28+4.3%$95.25+292.3%-48.5%$1.44B$9.34M-20.7530Trending NewsAnalyst RevisionBPMCBlueprint Medicines1.8452 of 5 stars$101.83-2.7%$127.22+24.9%-3.1%$6.51B$508.82M-94.29640News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.59-0.6%$22.00+18.3%N/A$6.28B$783.21M0.00N/AGap DownSRPTSarepta Therapeutics4.7943 of 5 stars$63.66+0.2%$157.95+148.1%-72.3%$6.26B$1.90B50.93840Positive NewsLEGNLegend Biotech3.5886 of 5 stars$33.40+0.7%$78.82+136.0%-38.5%$6.13B$627.24M-35.161,070Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTGTXTG Therapeutics3.9215 of 5 stars$37.68-13.3%$40.80+8.3%+108.5%$5.98B$329.00M-376.76290High Trading VolumeVRNAVerona Pharma3.264 of 5 stars$72.25-0.7%$81.50+12.8%+448.5%$5.84B$42.28M-37.6330News CoveragePositive NewsGap DownAXSMAxsome Therapeutics4.6882 of 5 stars$116.49+3.8%$169.87+45.8%+40.5%$5.73B$385.69M-19.45380News CoveragePositive NewsAnalyst UpgradeADMAADMA Biologics3.1443 of 5 stars$23.71+0.8%$22.50-5.1%+113.8%$5.63B$426.45M84.68530NUVLNuvalent2.7007 of 5 stars$75.43-2.6%$115.50+53.1%+3.4%$5.40BN/A-21.7440News CoveragePositive NewsGRFSGrifols3.1759 of 5 stars$7.45+1.4%N/A+0.8%$5.12B$7.21B6.3726,300News CoveragePositive NewsAnalyst Upgrade Related Companies and Tools Related Companies BPMC Competitors TLX Competitors SRPT Competitors LEGN Competitors TGTX Competitors VRNA Competitors AXSM Competitors ADMA Competitors NUVL Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Two drop-dead simple ways to play the gold boomIf you take a few minutes to check out the short research briefing Mark & I have put together, I’m confident y...Eagle Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JANX Stock Free JANX Stock Alerts